Novavax Gets a Federal Grant for Developing Its Novel Flu Vaccine

Novavax has landed a lucrative flu-vaccine contract with the U.S. government. It's worth $97 million over the first three years, and it can be extended for an additional two years, for a total contract value of $179.1 million. The technology could prove to be a lifesaver.

Five Biotechs for Under Five Bucks

As the year ends with the best yearly market gains since 2003, some investors are looking for increased risk-reward potential in the biotech sector. Capitalizing on this trend is risky, but it can be lucrative. Keep an eye on these notable names.